2-Deoxy-2-[fluorine-18]-fluoro-d-glucose (18F-FDG) positron emission tomography (PET)/ CT is useful for distinguishing benign from malignant lesions, and could predict early response to targeting agent in advanced NSCLC patients5,6F-FDG uptake within tumor cells is determined by the presence of increased glucose metabolism and hypoxia5, whereas upregulation of PD-L1 expression is partially regulated by tumor hypoxia7,8. This evidence concerns the gene CD274 and neoplasm.